Autoimmune Encephalitis in Acute Care—Pathology, Diagnosis, and Management

ABSTRACT Autoimmune encephalitis (AE) is characterized by immune‐mediated inflammation of the brain parenchyma, presenting with various neurological syndromes, including but not limited to seizures, altered consciousness, neuropsychiatric symptoms, and movement disorders. A significant proportion of patients with AE develop life‐threatening complications that require hospital and potentially ICU admission. These patients present unique diagnostic and therapeutic challenges, presenting with a range of neurological emergencies such as refractory status epilepticus, severe dysautonomia, coma, and respiratory failure. Diagnosis relies on a combination of clinical criteria, detection of autoantibodies in serum and cerebrospinal fluid, neuroimaging, and electroencephalography, though antibody‐negative AE poses considerable diagnostic difficulty. Management is centered on prompt initiation of first‐line immunotherapies (corticosteroids, plasma exchange, and intravenous immunoglobulin therapy) and escalation to second‐line or emerging targeted therapies (e.g., rituximab, cyclophosphamide, IL‐6 inhibitors, proteasome inhibitors) in refractory cases, alongside aggressive supportive care for neurological and systemic complications. The prognosis is variable and influenced by factors such as the specific autoantibody, the timeliness of treatment, and the severity of complications. Long‐term sequelae, including cognitive and psychiatric impairments, are common among survivors. This review provides a synthesis of current knowledge on AE in acute and intensive care. Given these diagnostic challenges and the potential for severe symptom presentation, the authors believe that this review is an essential addition to the discourse. This review covers pathophysiology, epidemiology, clinical manifestations, diagnostic approaches, immunotherapeutic strategies, management of critical complications, syndrome‐specific considerations, prognostication, intensive care unit‐related complications, and future research priorities to support optimal care.

Authors

Institutions

Publication Details

Journal
Advanced Science
Published
2026-03-29
DOI
https://doi.org/10.1002/advs.202519049
Primary Topic
Autoimmune Neurological Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Autoimmune Encephalitis in Acute Care—Pathology, Diagnosis, and Management

Subashini Suresh, Tonny Veenith, Shanika Samarasekera, Andrew MacDuff et al.
Advanced Science
Autoimmune Neurological Disorders and Treatments
article

Autoimmune Encephalitis in Acute Care—Pathology, Diagnosis, and Management

Subashini Suresh, Tonny Veenith, Shanika Samarasekera, Andrew MacDuff, Vikram Patil, Rajeev Krishnadas, William J. Scotton, David Okoh, Suneesh Thilak, Suresh Renukappa
article en

Abstract

ABSTRACT Autoimmune encephalitis (AE) is characterized by immune‐mediated inflammation of the brain parenchyma, presenting with various neurological syndromes, including but not limited to seizures, altered consciousness, neuropsychiatric symptoms, and movement disorders. A significant proportion of patients with AE develop life‐threatening complications that require hospital and potentially ICU admission. These patients present unique diagnostic and therapeutic challenges, presenting with a range of neurological emergencies such as refractory status epilepticus, severe dysautonomia, coma, and respiratory failure. Diagnosis relies on a combination of clinical criteria, detection of autoantibodies in serum and cerebrospinal fluid, neuroimaging, and electroencephalography, though antibody‐negative AE poses considerable diagnostic difficulty. Management is centered on prompt initiation of first‐line immunotherapies (corticosteroids, plasma exchange, and intravenous immunoglobulin therapy) and escalation to second‐line or emerging targeted therapies (e.g., rituximab, cyclophosphamide, IL‐6 inhibitors, proteasome inhibitors) in refractory cases, alongside aggressive supportive care for neurological and systemic complications. The prognosis is variable and influenced by factors such as the specific autoantibody, the timeliness of treatment, and the severity of complications. Long‐term sequelae, including cognitive and psychiatric impairments, are common among survivors. This review provides a synthesis of current knowledge on AE in acute and intensive care. Given these diagnostic challenges and the potential for severe symptom presentation, the authors believe that this review is an essential addition to the discourse. This review covers pathophysiology, epidemiology, clinical manifestations, diagnostic approaches, immunotherapeutic strategies, management of critical complications, syndrome‐specific considerations, prognostication, intensive care unit‐related complications, and future research priorities to support optimal care.

Advanced Science
University of Wolverhampton (GB), University Hospitals Birmingham NHS Foundation Trust (GB), University of Cambridge (GB), Cambridge School (PT), Bridge University (SS), The Royal Wolverhampton NHS Trust (GB), JSS Medical College and Hospital (IN)
Good health and well-being
Openalex Percentile: Top 2%
Autoimmune Neurological Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.